Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.45 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7209915 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1HPGDSMN1; SMN2SLC2A1 | |
| Bromide SCHEMBL7207307 | 0.84 | DRD2 (0.50) | SIGMAR1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Bromide SCHEMBL7210682 | 0.83 | DRD2 (0.54) | SIGMAR1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7207251 | 0.82 | KDM4E (0.51) | SIGMAR1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Bromide SCHEMBL7210192 | 0.82 | HTR1A (0.58) | SIGMAR1KDM4EHTR2AHTR1ACYP1A2 | |
| SCHEMBL8691758 | 0.80 | CHRM1 (0.63) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A | |
| Bromide SCHEMBL7209939 | 0.76 | KDM4E (0.51) | KDM4ESLC2A1HTR2AHTR1A | |
| SCHEMBL8691834 | 0.75 | HRH3 (0.58) | KDM4EALDH1A1HPGDSMN1; SMN2SLC2A1 | |
| SCHEMBL8692776 | 0.74 | SLC2A1 (0.56) | KDM4EALDH1A1HPGDSMN1; SMN2SLC2A1 | |
| SCHEMBL8694610 | 0.73 | KDM4E (0.67) | KDM4EALDH1A1HPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | claimed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | claimed |
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6313141-B1 | FOR THERAPY OF SCHIZOPHRENIA, PSYCHOTIC DEPRESSION, MANIA, PARKINSON'S DISEASE AND TARDIVE DISKINESIA | NEUROGEN CORPORATION | 2001-11-06 | — | — | US | disclosed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5972945-A | FOR TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | SLC6A3, DRD4, ADRA2C | SIGMAR1 56/4885HTR1A 44/4885KDM4E 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.